{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T06:41:47Z","timestamp":1787467307142,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:55:17Z","timestamp":1729371317000},"page":"182-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer"],"prefix":"10.1016","volume":"191","author":[{"given":"Sugantha Priya","family":"Elayapillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrita","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Moxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany N.","family":"Hannafon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.10.009_bb0010","series-title":"Cancer Facts and Figures 2018","author":"Society AC","year":"2018"},{"key":"10.1016\/j.ygyno.2024.10.009_bb0015","series-title":"SEER Cancer Statistics Factsheets: Cervix Uteri Cancer","author":"Institute NC","year":"2024"},{"issue":"7","key":"10.1016\/j.ygyno.2024.10.009_bb0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2024.10.009_bb0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1 Suppl 1","key":"10.1016\/j.ygyno.2024.10.009_bb0030","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.ygyno.2007.07.004","article-title":"Chemotherapy for recurrent cervical cancer","volume":"107","author":"Cadron","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"10103","key":"10.1016\/j.ygyno.2024.10.009_bb0035","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","article-title":"Topotecan in squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group","volume":"77","author":"Bookman","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.009_bb0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2009.07.024","article-title":"A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"115","author":"Fiorica","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2006.09.002","article-title":"Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study","volume":"104","author":"Garcia","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.009_bb0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ygyno.2003.10.045","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"92","author":"Muggia","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2024.10.009_bb0060","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.009_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"13","key":"10.1016\/j.ygyno.2024.10.009_bb0075","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","article-title":"Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways","volume":"21","author":"Morgan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.10.009_bb0080","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1200\/EDBK_159086","article-title":"Gynecologic cancers: emerging novel strategies for targeting DNA repair deficiency","volume":"35","author":"Kristeleit","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"11","key":"10.1016\/j.ygyno.2024.10.009_bb0085","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gde.2008.01.016","article-title":"DNA repair deficiency as a therapeutic target in cancer","volume":"18","author":"Martin","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"42","key":"10.1016\/j.ygyno.2024.10.009_bb0100","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.18632\/oncotarget.27008","article-title":"PARP-1 inhibitor modulate beta-catenin signaling to enhance cisplatin sensitivity in cancer cervix","volume":"10","author":"Mann","year":"2019","journal-title":"Oncotarget"},{"issue":"36","key":"10.1016\/j.ygyno.2024.10.009_bb0105","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2024.10.009_bb0110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01084-17","article-title":"High-risk alphapapillomavirus oncogenes impair the homologous recombination pathway","volume":"91","author":"Wallace","year":"2017","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.ygyno.2024.10.009_bb0115","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/1078-0432.CCR-13-3229","article-title":"Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways","volume":"21","author":"Morgan","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"7267","key":"10.1016\/j.ygyno.2024.10.009_bb0125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"24","key":"10.1016\/j.ygyno.2024.10.009_bb0135","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/MCB.00731-10","article-title":"Cdk1\/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity","volume":"30","author":"Matthess","year":"2010","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.009_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 Axis in Cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0145","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2024.10.009_bb0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ygyno.2024.10.009_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.009_bb0160","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7645","key":"10.1016\/j.ygyno.2024.10.009_bb0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","author":"Cancer Genome Atlas Research N, Albert Einstein College of M, Analytical Biological S, Barretos Cancer H, Baylor College of M, Beckman Research Institute of City of H","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.10.009_bb0170","series-title":"Clinical Trials; 2018\/07\/01","article-title":"Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)","author":"Berges","year":"2018"},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.009_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2024.10.009_bb0180","series-title":"Atr kinase inhibitor ceralasertib, CID=121596701 PubChem Database","author":"Information NCfB","year":"2024"},{"key":"10.1016\/j.ygyno.2024.10.009_bb0185","series-title":"Molecular and Cellular Biology, Genetics; 2017\/07\/01","article-title":"Abstract 2494: ATR inhibitor AZD6738 as monotherapy and in combination with olaparib or chemotherapy: defining pre-clinical dose-schedules and efficacy modelling","author":"Lau","year":"2017"},{"key":"10.1016\/j.ygyno.2024.10.009_bb0190","series-title":"Clinical Trials; 2018\/07\/01","article-title":"Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers","author":"Krebs","year":"2018"},{"issue":"12","key":"10.1016\/j.ygyno.2024.10.009_bb0195","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/annonc\/mdw635","article-title":"A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)","volume":"28","author":"Thaker","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.009_bb0205","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/IGC.0000000000000380","article-title":"A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology\/Gynecologic Oncology Group study","volume":"25","author":"Kunos","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2024.10.009_bb0210","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:53:10Z","timestamp":1733881990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"alternative-id":["S0090825824011594"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}